Business, energy, technology, markets and global industry news from Business News Today

Cedars-Sinai Medical Center

PharmaDeviceNews Cedars-Sinai Medical Center
Representative image of metastatic prostate cancer research as Syncromune’s investigational SYNC-T immunotherapy demonstrates 80% two-year survival and durable complete responses in an early Phase 1 clinical trial.
Pharma & Biotech

Kairos Pharma highlights 17.7-month progression-free survival with ENV-105 combination in metastatic prostate cancer

Kairos Pharma has presented interim Phase 2 findings showing substantially longer progression-free survival with ENV-105 plus apalutamide than with apalutamide alone. However, the number of patients in the analysis and key statistical details remain undisclosed, while a redesigned trial will test the treatment earlier in the course of resistance.

Read More
Dr. Raymond Douglas, MD, PhD, served as principal investigator in the international Tepezza trials that supported its FDA approval.
Features & Analysis

Dr. Raymond Douglas weighs Amgen’s Tepezza as Viridian’s Lumvoa widens TED choices

Amgen’s Tepezza is facing a broader thyroid eye disease treatment landscape after Viridian Therapeutics’ Lumvoa became another approved option, shifting attention toward how physicians may weigh evidence, safety, treatment burden and patient fit. Dr. Raymond Douglas, MD, PhD, who served as principal investigator in the international Tepezza trials that supported its United States Food and

Read More
OneLegacy’s partnership with OrganOx aims to expand access to normothermic liver perfusion technology and help Southern California transplant centres evaluate and preserve more donor livers for transplantation. Representative image.
Features & Analysis

Can OneLegacy’s OrganOx perfusion hub turn more donor livers into viable transplants?

OneLegacy is expanding OrganOx metra liver perfusion access across Southern California, testing whether a shared hub can increase transplant capacity.

Read More